<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MESNA</span><br/>(mes'na)<br/><span class="topboxtradename">Mesnex<br/></span><b>Classifications:</b> <span class="classification">antidote</span>; <span class="classification">detoxifying agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Detoxifying agent used to inhibit the hemorrhagic cystitis induced by ifosfamide. Analogous to the physiological cysteine-cystine
         system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In the kidney, thiol compound reacts chemically with urotoxic ifosfamide metabolites, resulting in their detoxification, and
         thus significantly decreases the incidence of hematuria.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis for ifosfamide-induced hemorrhagic cystitis. Not effective in preventing hematuria due to other pathologic conditions
         such as thrombocytopenia.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Reduces the incidence of cyclophosphamide-induced hemorrhagic cystitis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to mesna or other thiol compounds; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B); only if the benefits clearly outweigh any possible risk to fetus.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Use with Ifosfamide</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Dose = 20% of ifosfamide dose and is given at time of ifosfamide administration and 4 and 8 h after ifosfamide administration<br/><span class="rdage">Child:</span> <span class="rdroute"></span> Not established<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: To be effective, mesna must be administered with each dose of ifosfamide.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Add 4 mL of D5W, NS, or RL for each 100 mg of mesna to yield 20 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose by direct IV over 60 sec.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Carboplatin,</b>
<b>cisplatin,</b>
<b>ifosfamide with epirubicin.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B cholesteryl complex.</b>
</p>
<ul>
<li>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration.</li>
<li>Discard any unused portion of the ampul because drug oxidizes on contact with air.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Refrigerate diluted solutions or use within 6 h of mixing even though diluted solutions are chemically and physically stable
            for 24 h at 25° C (77° F).
         </li>
<li>Store unopened ampul at 15°30° C (59°86° F) unless otherwise specified.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span>
<span class="speceff-common">Bad taste in mouth, soft stools,</span> nausea, vomiting. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May produce a false-positive result in test for <span class="alt">urinary ketones.</span>
</p>
<h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Rapidly oxidized in liver to active metabolite dimesna; dimesna is further metabolized in kidney. <span class="typehead">Elimination:</span> 65% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> Mesna 0.36 h, dimesna 1.17 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor urine for hematuria.</li>
<li>Be aware that a false-positive test for urinary ketones may arise in patients treated with mesna. In this test, a red-violet
            color develops that, with the addition of glacial acetic acid, will turn to violet.
         </li>
<li>About 6% of patients treated with mesna along with ifosfamide still develop hematuria.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Mesna prevents ifosfamide-induced hemorrhagic cystitis; it will not prevent or alleviate other adverse reactions or toxicities
            associated with ifosfamide therapy.
         </li>
<li>Report any unusual or allergic reactions to physician.</li>
<li>Check with physician before using any new prescription or OTC medicine.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>